International Clinical Trial: Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07726069) titled 'Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department' on July 21.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: University of Illinois at Chicago

Condition: Cannabinoid Hyperemesis Syndrome

Intervention: Drug: Haloperidol

Recruitment Status: Not recruiting

Phase: Early Phase 1

Date of First Enrollment: November 2026

Target Sample Size: 100

Countries of Recruitment: United States

To know more, v...